{"Title": "A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis", "Year": 2018, "Source": "Nat. Med.", "Volume": "24", "Issue": 11, "Art.No": null, "PageStart": 1708, "PageEnd": 1715, "CitedBy": 67, "DOI": "10.1038/s41591-018-0224-2", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85056146022&origin=inward", "Abstract": "\u00a9 2018, The Author(s), under exclusive licence to Springer Nature America, Inc.Tuberculosis kills more people than any other infectious disease. Three pivotal trials testing 4-month regimens failed to meet non-inferiority margins; however, approximately four-fifths of participants were cured. Through a pooled analysis of patient-level data with external validation, we identify populations eligible for 4-month treatment, define phenotypes that are hard to treat and evaluate the impact of adherence and dosing strategy on outcomes. In 3,405 participants included in analyses, baseline smear grade of 3+ relative to <2+, HIV seropositivity and adherence of \u226490% were significant risk factors for unfavorable outcome. Four-month regimens were non-inferior in participants with minimal disease defined by <2+ sputum smear grade or non-cavitary disease. A hard-to-treat phenotype, defined by high smear grades and cavitation, may require durations >6 months to cure all. Regimen duration can be selected in order to improve outcomes, providing a stratified medicine approach as an alternative to the \u2018one-size-fits-all\u2019 treatment currently used worldwide.", "AuthorKeywords": null, "IndexKeywords": ["Antitubercular Agents", "Dose-Response Relationship, Drug", "Female", "Humans", "Kaplan-Meier Estimate", "Male", "Middle Aged", "Phenotype", "Risk Factors", "Sputum", "Treatment Outcome", "Tuberculosis, Multidrug-Resistant", "Tuberculosis, Pulmonary"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 2, "EID": "2-s2.0-85056146022", "SubjectAreas": [["Biochemistry, Genetics and Molecular Biology (all)", "BIOC", "1300"]], "AuthorData": {"57204546815": {"Name": "Imperial M.Z.", "AuthorID": "57204546815", "AffiliationID": "60023691", "AffiliationName": "University of California, San Francisco"}, "6507099787": {"Name": "Nahid P.", "AuthorID": "6507099787", "AffiliationID": "60023691", "AffiliationName": "University of California, San Francisco"}, "57203608245": {"Name": "Phillips P.P.J.", "AuthorID": "57203608245", "AffiliationID": "60023691", "AffiliationName": "University of California, San Francisco"}, "8951650600": {"Name": "Savic R.M.", "AuthorID": "8951650600", "AffiliationID": "60023691", "AffiliationName": "University of California, San Francisco"}, "7402854613": {"Name": "Davies G.R.", "AuthorID": "7402854613", "AffiliationID": "60020661", "AffiliationName": "University of Liverpool"}, "35493200400": {"Name": "Fielding K.", "AuthorID": "35493200400", "AffiliationID": "60031331", "AffiliationName": "London School of Hygiene and Tropical Medicine"}, "56376525800": {"Name": "Hanna D.", "AuthorID": "56376525800", "AffiliationID": "60022241", "AffiliationName": "Bill and Melinda Gates Foundation"}, "16946931600": {"Name": "Hermann D.", "AuthorID": "16946931600", "AffiliationID": "60022241", "AffiliationName": "Bill and Melinda Gates Foundation"}, "7102604862": {"Name": "Wallis R.S.", "AuthorID": "7102604862", "AffiliationID": "60018184", "AffiliationName": "Aurum Institute and ACT4TB/HIV"}, "57204578152": {"Name": "Johnson J.L.", "AuthorID": "57204578152", "AffiliationID": "60021578", "AffiliationName": "University Hospitals Cleveland Medical Center"}, "57203087999": {"Name": "Lienhardt C.", "AuthorID": "57203087999", "AffiliationID": "60108528, 60025735, 60000905, 60108488", "AffiliationName": "Unit\u00e9 Mixte Internationale TransVIHMI (UMI 233 IRD\u2013U1175 INSERM\u2013Universit\u00e9 de Montpellier), Institut de Recherche pour le D\u00e9veloppement (IRD)"}}}